STOCK TITAN

Mallinckrodt Plc - MNKPF STOCK NEWS

Welcome to our dedicated news page for Mallinckrodt Plc (Ticker: MNKPF), a resource for investors and traders seeking the latest updates and insights on Mallinckrodt Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mallinckrodt Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mallinckrodt Plc's position in the market.

Rhea-AI Summary
Mallinckrodt plc announces positive findings from a retrospective analysis on Acthar Gel treatment outcomes for African American and non-African American patients with symptomatic sarcoidosis. The study indicates similar health status improvement and symptom reduction in both groups, suggesting Acthar Gel as a viable treatment option for sarcoidosis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Mallinckrodt plc (MNK) emerges from Chapter 11 with a strengthened balance sheet and increased financial flexibility. Recent progress includes net sales and adjusted EBITDA growth, FDA acceptance of Acthar® Gel delivery device, positive momentum for Terlivaz®, and growth for Therakos®. The Specialty Generics segment benefits from vertical integration and U.S.-based manufacturing plants, with three FDA abbreviated new drug application approvals. The company reduced its total funded debt by approximately $1.9 billion and satisfied obligations to the Opioid Master Disbursement Trust II.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-100%
Tags
acquisition
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
conferences
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Mallinckrodt Plc

NYSE:MNKPF

MNKPF Rankings

MNKPF Stock Data

227.20M
10.36M
36.75%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
College Business Technology Park Cruiserath